Fewer than one in 10 individuals eligible to benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it releases its inaugural guidance on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for broader and more equitable availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be managed with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant barriers to widespread availability to the jabs that can assist patients in reducing significant weight, notes the organization.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic case, the supply of GLP-1 therapies could only cover about 100 million people – under 10% of those who need them, according to the WHO.
The guideline encourages governments and firms to expand availability, via measures such as voluntary licensing.
Exclusive production rights on a key compound – the main component of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Injections Work
The injections mimick a body's own hormone to slow digestion, suppress the appetite and increase satiety so users reduce food intake.
People typically see weight reduction in the initial weeks of starting on the regular doses.
Studies points to users may put most of the weight back on a year later of halting the medication, because their normal appetite come back.
Being carrying excess weight raises your chance for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity concerns individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, per the WHO.
